Advertisement

Treatment of established atherosclerosis during cholesterol feeding in monkeys

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      A semipurified diet containing 43% of the calories as fat and 1.2 mg of cholesterol/cal was fed to cynomolgus monkeys (Macaca fascicularis) for 6 months; the cholesterol content was reduced to 0.34 mg/cal for the next 18 months. During the latter period, the monkeys were assigned to 4 groups of 18 animals each and received the following dietary additions: A, none (controls); B, cholestyramine (5%, w/w); C, dextrothyroxine (0.003%); and D, Wy-14,643 (0.45%). Cholestyramine normalized plasma lipid levels and reduced the size of aortic and coronary atherosclerotic lesions in spite of the high-fat, high-cholesterol intake. Dextrothyroxine reduced cholesterolemia but did not modify the extent of arterial lesions. Wy-14,643 changed neither plasma cholesterol levels nor the extent of atherosclerosis.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. McGill Jr., H.C. The Geographic Pathology of Atherosclerosis. Williams and Wilkins, Baltimore, MD1968
        • Keys A.
        • Grande F.
        • Anderson J.T.
        Bias and misrepresentation revisited — Perspective on saturated fat.
        Amer. J. Clin. Nutr. 1974; 27: 188
        • Wissler R.
        • Vesselinovitch D.
        • Borenatajn J.
        • Hughes R.
        Regression of severe atherosclerosis in cholestyramine-treated rhesus monkeys with or without a low-fat, low-cholesterol diet.
        Circulation. 1975; 52: II-16
        • Malinow M.R.
        • McLaughlin P.
        • Naito H.K.
        • Lewis L.A.
        • McNulty W.P.
        Effect of alfalfa meal on shrinkage (regression) of atherosclerotic plaques during cholesterol feeding in monkeys.
        Atherosclerosis. 1978; 30: 27
        • Malinow M.R.
        • McLaughlin P.
        • Papworth L.
        • Naito H.K.
        • Lewis L.A.
        • McNulty W.P.
        A model for therapeutic intervention on established coronary atherosclerosis in a nonhuman primate.
        Adv. Exp. Med. Biol. 1976; 67: 3
        • Li J.C.R.
        Introduction to Statistical Inference.
        in: Edward Brothers, Inc, Ann Arbor, MI1957: 507
        • Rudel L.L.
        • Morris M.D.
        Determination of cholesterol using o-ophthalaldehyde.
        J. Lipid Res. 1973; 14: 364
      2. Tetrasorb-125, Instruction Manual, Abbott Laboratories, Radio-Pharmaceutical Products Division, North Chicago, IL.

        • Malinow M.R.
        • Corcoran A.
        Growth of the lens in howler monkeys (Alouatta caraya).
        J. Mammal. 1966; 47: 58
      3. Casdorph H.R. Cholestyramine – Treatment of Hyperlipidemic States. Charles C. Thomas, Springfield, IL1971: 243
        • Tennent D.M.
        • Siegel H.
        • Zanetti M.E.
        • Kuron G.W.
        • Ott W.H.
        • Wolf F.J.
        Plasma cholesterol lowering action of bile acid binding polymers in experimental animals.
        J. Lipid Res. 1960; 1: 469
        • Haskins S.A.
        • Van Itallie T.B.
        Cholestyramine resin therapy for hypercholesterolemia, clinical and metabolic studies.
        J. Amer. Med. Ass. 1965; 192: 289
        • Turner K.B.
        Studies on the prevention of cholesterol atherosclerosis in rabbits.
        J. Exp. Med. 1933; 58: 115
        • Kritchevsky D.
        • Tepper S.A.
        • Story J.A.
        Thyroid hormone and experimental atherosclerosis in rabbits.
        Atherosclerosis. 1976; 23: 249
        • Nandan R.
        • Fischer J.D.
        • Towery E.P.
        • Brown D.R.
        • Ganote C.E.
        • Jennings R.B.
        Effects of dextrothyroxine on hyperlipidemia and experimental atherosclerosis in beagle dogs.
        Atherosclerosis. 1975; 22: 299
        • The Coronary Drug Project Research Group
        Findings leading to further modifications of its protocol with respect to dextrothyroxine.
        J. Amer. Med. Ass. 1976; 220: 996
        • Santilli A.A.
        • Scotese A.C.
        • Tomarelli R.M.
        A potent antihypercholesterolemic agent: [4-chloro6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,463).
        Experientia (Basel). 1974; 30: 1110
        • Hollander M.
        • Wolfe D.A.
        Non-Parametric Statistical Methods.
        in: John Wiley and Sons, New York, NY1973: 115-120
        • Hollander M.
        • Wolfe D.A.
        Non-Parametric Statistical Methods.
        in: John Wiley and Sons, New York, NY1973: 131